Arrowhead Research Corporation (ARWR) Shares are Down -1.12%

Arrowhead Research Corporation (ARWR) : During the past 4 weeks, traders have been relatively bearish on Arrowhead Research Corporation (ARWR), hence the stock is down -3.65% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -1.64% relative to the S&P 500. The 4-week change in the price of the stock is -5.6% and the stock has fallen -1.12% in the past 1 week.

The stock has recorded a 20-day Moving Average of 1.59% and the 50-Day Moving Average is 10.84%.The 200 Day SMA reached 30% Arrowhead Pharmaceuticals, Inc. is up 23.34% in the last 3-month period. Year-to-Date the stock performance stands at 15.12%.


Arrowhead Research Corporation (ARWR) : Currently there are 6 street experts covering Arrowhead Research Corporation (ARWR) stock. The most bullish and bearish price target for the stock is $15 and $6 respectively for the short term. The average price target of all the analysts comes to $10.42. The estimated standard deviation from the target is $3.85.

For the current week, the company shares have a recommendation consensus of Buy. Arrowhead Research Corporation (NASDAQ:ARWR): stock was range-bound between the intraday low of $7.02 and the intraday high of $7.27 after having opened at $7.11 on Fridays session. The stock finally closed in the red at $7.11, a loss of -0.84%. The stock remained in the red for the whole trading day. The total traded volume was 1,467,148 shares. The stock failed to cross $7.27 in Fridays trading. The stocks closing price on Thursday was $7.08.

Arrowhead Research Corporation develops drugs to treat intractable diseases by silencing the genes that cause them. Using the broadest portfolio of RNA chemistries and efficient modes of delivery, the Companys therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Companys drug candidate in clinical development is ARC-520, which is designed to treat chronic hepatitis B infection by inhibiting the production of all HBV gene products. The goal is to reverse the immune suppression that prevents the body from controlling the virus and clearing the disease. Its second clinical candidate is ARC-AAT, a treatment for a rare liver disease associated with a genetic disorder that causes alpha-1 antitrypsin deficiency.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.